A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Colorectal Cancer|Solid Tumor|Glioblastome Multiforme
Interventions: DRUG: Poziotinib Hydrochloride|DRUG: Loperamide
Sponsor: Spectrum Pharmaceuticals, Inc